TLY-012 is under clinical development by D&D Pharmatech and currently in Phase I for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase I drugs for Systemic Sclerosis (Scleroderma) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TLY-012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TLY-012 is under development for the treatment of NASH-liver fibrosis and non-alcoholic steatohepatitis (NASH),chronic pancreatitis and systemic sclerosis. The drug candidate is a pegylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated TRAIL). It acts by targeting death receptor 5 (DR5).
It was also under development for liver cirrhosis.
D&D Pharmatech overview
D&D Pharmatech is a biotechnology company that develops and manufactures drugs for the treatment of neurodegenerative and fibrotic diseases. It also engaged in research and diagnostics of central nervous system drug. D&D Pharmatech is headquartered in Seongnam, Gyeonggi, South Korea.
For a complete picture of TLY-012’s drug-specific PTSR and LoA scores, buy the report here.